With FDA input pending, the companies are targeting a Phase 3 trial launch in the first half of 2026
The structural inversion of dominant components GHK-Cu leading in GLOW, BPC-157 leading in KLOW is the defining distinction
They didnt
Common side effects of BPC-157 arent usually serious and may include: Mild injection site reactions (itching, redness, swelling, pain, etc.) Headaches Dizziness Nausea In rare cases, patients may experience fevers, blistering at the injection site, muscle aches, rashes, vomiting, hives, or other signs of an allergic reaction
Both are manageable with a single syringe
Exposure to extreme temperatures, either hot or cold, can degrade the waters quality and effectiveness